iPS-NSC cells vs TED-A9 (A9-DPC)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Parkinson's Disease

Shared mechanism: dopaminergic neuron replacement · full Parkinson's Disease pipeline

iPS-NSC cells

Developed by Allife Medical Science and Technology

Phase 1 in Parkinson's Diseasecell therapy
Weak signal

NCT03815071 · Phase 1 · status unknown

This is a small, single-arm, unblinded study of 10 participants with no control group, designed to check safety rather than test efficacy against a comparator, and results have not yet been posted.

No aligned efficacy figure on record for this race.

TED-A9 (A9-DPC)

Developed by S.Biomedics

Phase 1/2 in Parkinson's Diseasecell therapy
Weak signal

NCT05887466 · Phase 1/2 · completed

The study assigned six participants to each of two dose groups without randomization, blinding, or a placebo or active comparator. Its primary outcomes focused on adverse events and transplant failure or rejection. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: February 2029 · NCT06477744 (registry estimate)

Reported efficacy

Occurrence of treatment-emergent adverse events (TEAEs) after administration of the IP (Up to 96 Weeks (24 months) after IP administration); Failure or rejection of transplantation (Week 12 (3 months)); Failure or rejection of transplantation (Week 24 (6 months)); Failure or rejection of transplantation (Week 48 (12 months)); Failure or rejection of transplantation (Week 96 (24 months)); Occurrence of bleeding (Week 12 (3 months)); Occurrence of bleeding (Week 24 (6 months)); Occurrence of bleeding (Week 48 (12 months)); Occurrence of bleeding (Week 96 (24 months)); Occurrence of infection (Week 12 (3 months)); Occurrence of infection (Week 24 (6 months)); Occurrence of infection (Week 48 (12 months)); Occurrence of infection (Week 96 (24 months)); Occurrence of adverse event of special interest (AESI)* after administration of the IP (Up to 96 Weeks (24 months) after IP administration): Primary endpoint (occurrence of TEAEs) at the 12-month interim readout: 1 of 12 participants had a mild hemorrhage unrelated to the transplant site; no cell/graft-related adverse events or other neurological abnormalities/side effects reported.

Result source: NCT05887466

Results for Parkinson's Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointiPS-NSC cellsTED-A9 (A9-DPC)
OFF time, change—Not reported—Not reported
ON time without troublesome dyskinesia, change—Not reported—Not reported
UPDRS Part III, change—Not reported—Not reported
MDS-UPDRS Part II, change—Not reported—Not reported

OFF time, change

iPS-NSC cells
—Not reported
TED-A9 (A9-DPC)
—Not reported

ON time without troublesome dyskinesia, change

iPS-NSC cells
—Not reported
TED-A9 (A9-DPC)
—Not reported

UPDRS Part III, change

iPS-NSC cells
—Not reported
TED-A9 (A9-DPC)
—Not reported

MDS-UPDRS Part II, change

iPS-NSC cells
—Not reported
TED-A9 (A9-DPC)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

iPS-NSC cells: no structured comparison results are available for Parkinson's Disease.

TED-A9 (A9-DPC): no structured comparison results are available for Parkinson's Disease.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: iPS-NSC cells's landscape · TED-A9 (A9-DPC)'s landscape